Importance of VDR polymorphism in the severity of novel coronavirus infection
Vitamin D, an important nutrient for the body, has been attracting attention in connection with the new coronavirus infection (COVID-19). Research shows that the severity of COVID-19 can vary widely, from mild symptoms to severe pneumonia and even death. It has been suggested that severely ill patients with COVID-19 may be more susceptible to vitamin D deficiency. Interestingly, serum vitamin D levels may not significantly influence disease severity. Instead, it is thought that vitamin D, which is produced in the lungs, plays a role in regulating the immune response and may influence the severity of coronavirus infection.
VDR polymorphism, a genetic variation in the vitamin D receptor gene, has been shown to influence immune responses. Patients with her VDR polymorphism infected with COVID-19 often report symptoms such as difficulty breathing, kidney damage, and high blood pressure. Additionally, fluctuations in vitamin D levels have been associated with respiratory infections. Understanding these genetic variables may help develop effective treatment plans, identify at-risk individuals, and guide future research on COVID-19 management.
Analysis of VDR polymorphisms in moderate and severe COVID-19 patients
To further investigate the relationship between VDR polymorphisms and COVID-19 severity, a study was conducted using patients from the ongoing Isfahan COVID Cohort (ICC). The study included a total of 176 patients with COVID-19, of whom 91 were non-hospitalized and 85 were hospitalized. Convenience sampling was used to select eligible patients who were at least 19 years of age and had positive RT-PCR findings.
Hospitalized patients were classified as having moderate or severe disease based on World Health Organization criteria, while non-hospitalized patients were asymptomatic. The study was approved by the National Institute of Medical Research and Development (NIMAD) in Tehran, Iran, and all subjects provided written informed consent.
Lifestyle, socio-economic, demographic, and medical record data were collected through interviews conducted by experienced health center interviewers. Blood samples were taken and DNA extracted, which he analyzed for VDR polymorphisms using ARMS PCR and Sanger sequencing. Statistical analyzes were performed using various tests and regression techniques.
Findings and implications
The study found that the hospitalized group had a lower mean age and waist circumference than the non-hospitalized group, but also had lower physical activity levels. Additionally, the hospitalized group had higher prevalence of hypertension and diabetes, but fewer smokers, compared with the non-hospitalized group.
Among the VDR gene polymorphisms studied, the TT genotype of rs11568820 was found to be significantly less in the hospitalized group (3.5%) compared to the non-hospitalized group (17.6%). This genotype remained inversely associated with hospitalization due to COVID-19, even after adjusting for coronary heart disease, smoking, and body mass index. Meanwhile, no significant differences were observed for the other studied VDR gene polymorphisms.
It is important to note that this study focused on the distribution of VDR SNPs across different COVID-19 severity levels. This is a unique perspective that has not been extensively explored in previous research. However, the descriptive nature of this study limits its ability to establish a causal relationship between COVID-19 severity and VDR polymorphisms. Furthermore, the absence of measurements of serum vitamin D levels and information on immunological factors precludes a comprehensive interpretation of the results.
Larger and more comprehensive studies with diverse patient groups are needed to validate these findings and better understand the role of VDR polymorphisms in the severity of COVID-19 infection. Nevertheless, this study successfully identified the TT genotype of rs11568820 as a protective factor against severe COVID-19 strains. This knowledge of genetic predispositions could potentially contribute to the development of customized treatment plans in the fight against COVID-19.
